STANFORD, CA – April 24, 2024 – A scientific revelation, nearly four decades in the making, has fundamentally reshaped our understanding of cancer immunity. Researchers at Stanford University have discovered that erythropoietin (EPO), a protein long recognized for its vital role in stimulating red blood cell production, harbors a surprising and critical function: actively suppressing the immune system’s ability to fight cancer. This groundbreaking finding, published online today in Science, illuminates a previously unknown mechanism by which tumors evade immune detection and offers a promising new avenue for cancer treatment.
The research demonstrates that by blocking EPO’s activity, previously "cold," or immune-resistant, liver tumors in mice were dramatically transformed into "hot" tumors, teeming with an influx of cancer-fighting immune cells. When this intervention was combined with an existing immunotherapy designed to further activate these immune cells, the results were astonishing: complete regression of existing liver tumors in the vast majority of treated mice, who subsequently lived for the entire duration of the experiment. In stark contrast, control animals succumbed to the disease within weeks.
“This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer,” stated Dr. Edgar Engleman, a professor of pathology and medicine and the senior author of the research. “I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials.” The study’s lead author is basic life research scientist Dr. David Kung-Chun Chiu.
A Decades-Old Protein with a New Identity: The Chronology of Discovery
The journey to this pivotal discovery stretches back decades, weaving through established biological functions and perplexing clinical observations. EPO has been a cornerstone of medical understanding for its role in hematopoiesis, the process of red blood cell formation. Its ability to stimulate erythrocyte production has been therapeutically harnessed for patients suffering from anemia, particularly those with kidney disease or undergoing chemotherapy. For nearly 40 years, its primary identity in medicine has been firmly anchored to this life-sustaining function.
From Red Blood Cells to Immune Modulation
The initial identification of EPO for its hematopoietic capabilities marked a significant milestone in biology. Its mechanism, involving binding to the erythropoietin receptor (EPOR) on progenitor cells in the bone marrow, was well-characterized, leading to its widespread use as a therapeutic agent. For decades, the scientific community primarily viewed EPO through this lens, overlooking or misinterpreting any broader biological implications. The idea that a protein so intrinsically linked to blood cell formation could also be a master regulator of immune responses in cancer was, until now, largely inconceivable.
The Troubling Link to Cancer Growth: A 2007 FDA Warning
However, the narrative surrounding EPO began to acquire a troubling undertone more than a decade ago, specifically in the context of cancer patients. Clinical observations revealed a disturbing trend: when EPO was administered to anemic cancer patients to boost their red blood cell counts and alleviate fatigue, it appeared to accelerate tumor growth. This unexpected and adverse effect was so pronounced that in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box" warning label on EPO-stimulating drugs, cautioning against their use in individuals with certain cancers.
This clinical conundrum presented a significant challenge. While EPO was clearly implicated in promoting cancer progression, the precise biological mechanism remained elusive. Researchers observed a clear correlation between patient prognosis and the levels of naturally occurring EPO and its receptor (EPOR) within tumors – higher levels consistently predicted worse outcomes. “Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were,” Dr. Engleman recalled. “But the connection between EPO and cancer immunity was never made until now.” The scientific community struggled to reconcile EPO’s known role in red blood cell growth with its newfound, detrimental influence on tumor dynamics. The prevailing assumption was that EPO was merely acting as a growth factor for cancer cells, perhaps stimulating their proliferation directly or indirectly through angiogenesis. The possibility of an immune-modulatory role was simply not on the radar.
The "Aha!" Moment: Unraveling the Immunosuppressive Mechanism
It took a dedicated and persistent effort, involving extensive experimentation and a willingness to challenge established paradigms, for Dr. Engleman’s team to uncover the missing piece of the puzzle. “In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor,” Engleman emphasized.
The breakthrough stemmed from a focused investigation into liver cancer, a disease notoriously difficult to treat with conventional immunotherapies. Dr. David Kung-Chun Chiu, the lead author, meticulously developed and studied various genome editing techniques to create sophisticated mouse models of liver cancer. These models were designed to accurately recapitulate specific genetic mutations, histological features, and responses to approved therapies observed in distinct subtypes of human liver cancers. Tumor formation in these models was initiated either by injecting a combination of DNA encoding proteins associated with liver cancer into the animals’ tail veins or by directly implanting liver cancer cells into the animals’ livers. This meticulous approach allowed the researchers to precisely control and observe the interplay between genetic factors, tumor microenvironment, and immune responses.
The primary interest of the research team was to understand the varied responses of these liver tumors to a common and powerful immunotherapy targeting the programmed cell death protein 1 (PD-1) on immune cells, particularly T cells. Anti-PD-1 therapies, such as the commercially available Keytruda, work by blocking PD-1, thereby preventing cancer cells from deactivating the T cells that are poised to attack them. While these therapies have revolutionized the treatment of several cancers, including melanoma, Hodgkin’s lymphoma, and some types of lung cancer, they have largely failed in a significant majority of other tumor types, such as most liver, pancreas, colon, breast, and prostate cancers. These unresponsive tumors are often described as "cold" because they lack a substantial immune cell infiltration, rendering immunotherapies ineffective.
It was in the context of these "cold" liver tumors that the unexpected role of EPO began to emerge. The researchers observed that, consistent with human liver cancers, certain combinations of genetic mutations in their mouse models led to the development of liver tumors that were largely ignored by the immune system. These immune-privileged, or "cold," tumors failed to shrink when treated with anti-PD-1 therapy due to the scarcity of T cells within the tumor microenvironment. Conversely, other mutations resulted in "hot," or "inflamed," tumors, which were replete with T cells and highly sensitive to anti-PD-1 treatment, leading to robust anti-cancer immune responses.
The crucial observation was that these immune-resistant "cold" tumors consistently displayed elevated levels of EPO compared to their "hot" counterparts. This increase, the researchers hypothesized, was likely a consequence of the oxygen-poor microenvironment—a condition known as hypoxia—that is prevalent in rapidly growing, poorly vascularized tumors. Hypoxia is a well-known trigger for the production of various proteins in cancer cells, which, in turn, can ramp up the production of EPO in an attempt to generate more red blood cells and thus combat the low oxygen levels. This physiological response, intended to maintain oxygen homeostasis, now appeared to be hijacked by the tumor to its own advantage.
“Hypoxia in tumors has been studied for decades,” Engleman noted. “It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor.” This realization marked the turning point, prompting the team to investigate the potential immune-modulatory role of EPO directly.
Supporting Data and Mechanisms: The Science Behind the Breakthrough
The detailed investigations conducted by Dr. Engleman and Dr. Chiu’s team have provided compelling evidence for EPO’s immunosuppressive role and meticulously elucidated the underlying molecular mechanisms.
The Enigma of "Cold" vs. "Hot" Tumors
The concept of "cold" and "hot" tumors is central to understanding the varying efficacy of modern immunotherapies. "Hot" tumors are characterized by a significant infiltration of T cells and other immune cells, indicating an ongoing immune response against the cancer. These tumors are often responsive to checkpoint inhibitors like anti-PD-1, which release the brakes on T cells, allowing them to effectively kill cancer cells. In contrast, "cold" tumors exhibit a sparse immune cell presence and are largely ignored by the immune system. This lack of immune infiltration renders them resistant to therapies that rely on activating existing immune cells, representing a major hurdle in cancer treatment. Cancers of the liver, pancreas, colon, breast, and prostate often fall into this "cold" category, highlighting the urgent need for strategies to convert them into "hot" tumors.
Hypoxia, EPO, and the Immunosuppressive Loop
The researchers’ pivotal discovery lies in the intricate interplay between tumor hypoxia, EPO production, and the subsequent reprogramming of immune cells. They found that in the oxygen-deprived microenvironment of "cold" tumors, cancer cells dramatically increase their production and secretion of EPO. This secreted EPO then acts locally within the tumor, binding to specific receptors (EPOR) expressed on the surface of immune cells called macrophages.
Macrophages are versatile immune cells that can adopt different phenotypes depending on their microenvironment. In the presence of EPO, the researchers observed that macrophages switch to an immunosuppressive role. This phenotypic shift is critical: these reprogrammed macrophages actively "shoo away" cancer-killing T cells, preventing their infiltration into the tumor. Furthermore, they actively tamp down the activity of any T cells that do manage to enter the tumor, effectively creating an immune-privileged sanctuary for the cancer. This EPO-mediated crosstalk between tumor cells and macrophages establishes a vicious cycle, where hypoxia drives EPO production, which in turn fuels immune suppression, perpetuating the "cold" tumor phenotype and allowing the cancer to thrive unchecked.
Compelling Experimental Evidence
To rigorously test their hypothesis, the researchers conducted a series of elegant and conclusive experiments:
-
Validating EPO-Prognosis Link in Humans: First, they turned to existing human cancer databases, confirming that elevated levels of EPO are indeed correlated with poorer survival outcomes in patients across a range of cancer types, including those of the liver, kidney, breast, colon, and skin. This reinforced the clinical relevance of their observations in mice.
-
Manipulating EPO Production in Tumors: The team then genetically tinkered with the ability of tumor cells in their mouse models to produce EPO. They found that mutations that had previously led to the development of "cold" tumors instead resulted in "hot" tumors when these tumor cells were modified to be unable to make EPO. This demonstrated that EPO production by tumor cells was directly responsible for the "cold" phenotype. Conversely, "hot" tumors that had previously been successfully eradicated by the immune system thrived and progressed aggressively when they were engineered to make elevated levels of EPO, proving EPO’s causal role in immune evasion.
-
Blocking the EPO-Macrophage Pathway: Further exhaustive research focused on the specific interaction between EPO and macrophages. The critical importance of this EPO-moderated crosstalk between tumor cells and macrophages was vividly demonstrated when the researchers studied the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. In these experiments, mice bearing "cold" liver tumors that received either a control treatment or anti-PD-1 therapy alone showed dismal survival, with none living more than eight weeks after tumor induction. However, when mice with macrophages unable to make the EPO receptor were treated, 40% lived for 18 weeks after tumor induction, at which point the experiment was terminated. The most striking results emerged when anti-PD-1 treatment was administered to mice that lacked the EPO receptor on their macrophages: all animals lived for the duration of the experiment, achieving complete and lasting tumor regression.
“It’s simple,” Dr. Engleman summarized. “If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment.” This unequivocal evidence underscores EPO’s central role in rendering tumors immune-resistant and highlights the transformative potential of targeting this pathway.
Broader Applicability to Human Cancers
While the initial work was conducted in mouse models, the researchers emphasize that there are strong indications that EPO plays a similar, critical role in many types of human cancers. The historical clinical data, including the 2007 FDA black box warning, and the correlations found in human cancer databases, lend significant weight to the translatability of these findings. The conserved nature of EPO and its receptor across species, coupled with the fundamental biological processes involved (hypoxia, immune cell function), suggests that this newly discovered mechanism is likely a generalizable feature of cancer immune evasion in humans. This offers immense hope for patients with a wide array of currently untreatable or poorly responsive cancers.
Official Responses and Expert Perspectives
The publication of this research in Science immediately signals its profound impact and significance within the scientific community. The findings are poised to ignite new research directions and accelerate the development of novel therapeutic strategies.
Researchers’ Enthusiasm and Hope
Dr. Edgar Engleman’s palpable excitement reflects the potential paradigm shift this discovery represents. His statement, "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials," conveys a deep sense of optimism. This sentiment is shared by the entire research team, who have dedicated years to unraveling this complex biological puzzle. The recognition that a widely studied protein could harbor such a critical, yet overlooked, function in cancer immunity underscores the ongoing capacity of basic research to yield unexpected and transformative insights.
The Journey Ahead: Clinical Translation
The next crucial step is the translation of these promising preclinical findings into human clinical trials. This will involve rigorous development and testing of drugs that can safely and effectively target the EPO signaling pathway in human patients. The success in mouse models, particularly the complete regression achieved with combination therapy, provides a strong impetus for this expedited translational effort. The scientific community will be watching closely as these potential therapies move through the pipeline.
Addressing Past Concerns and New Possibilities
This new understanding also offers a powerful reinterpretation of the 2007 FDA black box warning regarding EPO use in cancer patients. What was once viewed as a mysterious tumor-promoting effect can now be understood through the lens of immune suppression. The prior observations that EPO accelerated tumor growth were not incorrect, but the underlying mechanism was misattributed or incomplete. This new research doesn’t contradict the past, but rather enriches it, providing a mechanistic explanation for why EPO was detrimental in cancer patients. This clarity could pave the way for a more nuanced approach to EPO management in cancer care, potentially allowing for its careful use in specific contexts while aggressively blocking its immunosuppressive effects.
Implications and Future Directions for Cancer Treatment
The discovery of EPO’s role in dampening the immune response to cancer holds profound implications for the future of oncology, promising to expand the reach of immunotherapy and offer new hope for patients with previously intractable tumors.
Novel Therapeutic Strategies
Dr. Engleman and his colleagues are already actively designing treatments targeting EPO signaling in human cancers, exploring several promising avenues:
-
Non-specific EPO Targeting: One approach involves non-specifically targeting the EPO protein itself, aiming to lower its overall levels or block its activity. While this strategy carries the potential side effect of anemia (due to EPO’s role in red blood cell production), Dr. Engleman speculates that for an effective cancer therapy, this might be an "acceptable trade-off." The severity of anemia and its manageability would be critical factors in evaluating this approach. However, if such a treatment could convert aggressive, untreatable cancers into curable ones, the benefits might far outweigh the risks.
-
Selective Macrophage EPO Receptor Blocking: A more refined and potentially safer strategy is to selectively block the EPO receptors specifically on the surfaces of macrophages within the tumor microenvironment. This targeted approach would aim to disrupt the immunosuppressive crosstalk between tumor cells and macrophages without interfering with EPO’s systemic role in red blood cell formation, thereby minimizing the risk of anemia and other systemic side effects. Developing highly specific inhibitors that can effectively target EPOR on macrophages in the tumor while sparing other tissues will be a key challenge for medicinal chemists.
Expanding Immunotherapy’s Reach
Perhaps one of the most exciting implications of this discovery is its potential to revolutionize the treatment of "cold" tumors. By converting these immune-resistant tumors into "hot" ones, targeting EPO signaling could make a much wider range of cancers responsive to existing immunotherapies like anti-PD-1. This could transform the treatment landscape for cancers of the liver, pancreas, colon, breast, and prostate, which currently respond poorly to these groundbreaking treatments. The combination of an EPO-targeting agent with a PD-1 inhibitor could become a powerful new regimen, effectively breaking down the immune barriers erected by the tumor.
Moreover, this research opens up broader investigations into other factors that contribute to tumor hypoxia and immune evasion. Understanding the full spectrum of how tumors hijack physiological processes for their survival could lead to a new generation of multi-pronged therapeutic approaches.
Collaborative Efforts and Funding
The collaborative nature of modern scientific research is evident in this study. Researchers from the New York Blood Center and the pharmaceutical company ImmunEdge Inc. contributed significantly to the research, highlighting the synergy between academic institutions and industry in driving medical innovation. The study received substantial financial support from the National Institutes of Health (NIH) through grants R01CA262361, P01CA244114, U54CA2745115, and P01HL149626, underscoring the importance and potential impact recognized by national funding bodies.
Ethical Considerations and Financial Disclosures
In the interest of transparency, the researchers have disclosed their affiliations and potential conflicts of interest. Dr. Chiu is a co-founder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of ImmunEdge Inc. Both Dr. Chiu and Dr. Engleman are Stanford-affiliated inventors of PCT/US2023/063997, entitled "EPO receptor agonists and antagonists." Such disclosures are standard practice in scientific publishing and ensure that potential financial interests are transparently communicated, allowing the scientific community and the public to assess the research context fully.
Dr. Engleman’s enduring optimism encapsulates the significance of this work: “I continue to be amazed by this finding. Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies.” This breakthrough stands as a testament to the power of persistent inquiry and the transformative potential of uncovering the hidden roles of even the most familiar biological molecules. As this research moves from the lab to the clinic, it carries the promise of redefining how we approach cancer treatment, offering a beacon of hope for countless patients worldwide.
About the Author
